Addendum to Service Agreement with Dr. Meier-Ewert dated May 1, 2003




			
	

	  	Exhibit 10.19
	  	 + 49 89 8565 2600 tel.

	  	 + 49 89 8565 2610 fax

	  	 www.gpc-biotech.com

	  	 
	  	 GPC Biotech AG
 Postfach 1455
 82143 Planegg
 Germany
 Fraunhoferstrasse 20
 82152 Martinsried/Munich
 Germany


  
 ADDENDUM TO
SERVICE AGREEMENT 
  
 The Service Agreement of November 16, 2001 between
GPC Biotech AG, Fraunhoferstr. 20, 82152 Martinsried/Planegg (hereinafter “Company”) and Dr. Sebastian Meier-Ewert, Ringstrasse 22a, 82538 Gelting (hereinafter “Management Board Member”) is hereby amended with immediate effect
pursuant to § 15, Para. 1. 
  
 The Addendum to Service Agreement of 9/10/2002
is hereby rescinded and replaced by the following § 12 of the Service Agreement: 
  
 § 12 
  
 Change of
Control 
  

	1.	In the event of a “change of control” (as defined below), all stock options, convertible bonds, phantom stock, and all other rights that carry an entitlement to acquire
stock in the Company that have been issued to the Management Board Member up to that time shall vest (“accelerated vesting”) as soon as one shareholder or group of shareholders has acquired the majority of the voting rights in the Company,
and by no later than the time at which said acquisition has been reported to the Federal Office for Financial Services Supervision (BaFin). In the event of a merger with other companies, the aforementioned rights vest when the merger is recorded in
the Commercial Register. Moreover, the Company shall not avail itself of any of the termination rights provided in the terms of the aforementioned stock options, convertible bonds, or phantom stocks for a period of at least 5 years following a
“change of control” or until maturity. 

  
 The other obligations of the Company toward the Management Board Member arising from the present Agreement remain unaffected by such a takeover. The other terms of the stock options, convertible bonds, phantom stock, and all other rights
that carry an entitlement to acquire stock in the Company remain in force unchanged. 
  

					
	 	 	 GPC Biotech AG
	  	 Management Board:

	 	 	 Munich District Court HRB 119 555
	  	 Prof. Dr. Bernd Seizinger (CEO)

	 	 	 VAT ID No.: DE 190 457 435
	  	 Dr. Elmar Maier

	 	 	 	  	 Dr. Sebastian Meier-Ewert

	 	 	 Deutsche Bank AG, Munich (Code 700 700 10), Acct. No. 199 01 18
	  	 Dr. Mirko Scherer

	 	 	 Dresdner Bank AG, Munich (Code 700 800 00), Acct. No. 300 906 300
	  	 
	 	 	 HypoVereinsbank AG, Munich (Code 700 202 70), Acct. No. 272 66 45
	  	Chairman of the Supervisory Board
	 	 	 	  	 Dr. Jürgen Drews


  










	2.	Should the Company terminate the Service Agreement for any reason other than cause pursuant to § 13, Para. 1 of the Service Agreement within eighteen (18) months following the
“change of control,” or should the Management Board Member terminate the Service Agreement within that same period for one or more of the following reasons: 

  

	 	a)	reduction in the annual salary and/or in the envisaged bonus; 

  

	 	b)	loss of the position of chief scientific officer or assignment of unreasonable responsibilities (“material diminution”); or 

  

	 	c)	change of the Management Board Member’s place of work to a new location that is more than 50 km from his place of work at the time of the “change of control”
(currently Fraunhoferstr. 20, 82152 Martinsried/Planegg); 

  
 then a one-time payment shall be due to the Management Board Member within 30 days, beginning with the last day of the Service Agreement. This payment shall amount to 175% (one hundred seventy-five percent) of the
total of 
  

	 	a)	one annual salary at the time of the “change of control” or at a later time if the annual salary is increased; and 

  

	 	b)	the average of the two annual bonuses last received prior to the date of the “change of control.” If the Management Board Member has not received two annual bonuses, the
last annual bonus payment is used as the basis for calculation. 

  
 This payment can be foregone if the Company and the Management Board Member agree to a higher settlement. 
  

	3.	“Change of control” is defined here as: a) the takeover, exchange, or other transfer of more than 50% of the outstanding voting rights in the Company (in one or more
steps) to a single shareholder or group of shareholders, or b) the merger of the Company with other companies (e.g., as part of a “merger” or “reverse merger”), in which the Company holds less than 50% of the outstanding voting
rights in the new company. 

  

					
	 Martinsried/Planegg, 5/1/2003
	 	 	 	 
			
	 Management Board Member
	 	 	 	 GPC Biotech AG

			
	 /s/ Dr. Sebastian Meier-Ewert
	 	 	 	 /s/ Prof. Dr. Jürgen Drews

	 Dr. Sebastian Meier-Ewert
	 	 	 	 Prof. Dr. Jürgen Drews
 Chairman of the Supervisory Board